Faculty Opinions recommendation of Empagliflozin and progression of kidney disease in type 2 diabetes.

2016 ◽  
Author(s):  
Enyu Imai
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Progression Of Kidney Disease

P0751METFORMIN, A CLASSIC TREATMENT FOR TYPE 2 DIABETES WITH POSSIBLE RENOPROTECTIVE EFFECTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Adriana Acosta Barrios ◽  
Marian Goicoechea ◽  
Eduardo Verde ◽  
Ángela González-Rojas ◽  
Andres Delgado ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Experimental Studies ◽  
Diabetic Patients ◽  
Metformin Treatment ◽  
End Point ◽  
Progression Of Kidney Disease

Abstract Background and Aims Metformin is the antidiabetic of choice in patients with type 2 diabetes mellitus. Experimental studies and clinical observations have shown that metformin could have a beneficial effect on the progression of kidney disease through the activation of cAMP due to its anti-inflammatory, antifibrotic, and anti-oxidative action. The objective was to compare the progression of CKD in diabetic patients with or without metformin as antidiabetic in their treatment and the prevalence of cardiovascular events in both groups. Method Unicentric retrospective observational analysis. Inclusion criteria: outpatients seen in nephrology consultation during the year of 2012 with diabetes mellitus and stage 3 CKD. Renal, cardiovascular outcomes and mortality were analyzed between patients treated with / without metformin. Median follow-up of 76.5 months (41-84). Renal end-point: estimated glomerular filtration rate drop (MDRD-4) by 50% and / or start of dialysis program. Cardiovascular end-point: ischemic heart disease, stroke, arterial revascularization and / or amputation. Cardiovascular or any cause mortality. Results 148 patients (96M, 52W) with a mean age of 75±9 years and an eGFR of 40±9 ml / min / 1.73 m2 were included. In relation to hypoglycemic therapy: 45 received metformin, 61 insulin and 31 DPP4i. 80% received treatment with RAAS blockers. After the follow-up, the progression of the renal disease was greater in patients who did not receive metformin: eGFR fall of -7.0±16 vs -0.15±16 ml / min in those treated with metformin (p = 0.019). 25 patients in the group without metformin suffered a renal event vs. 5 in the metformin group (logRank: 4.186, p = 0.045). In the Cox analysis, metformin treatment decreases the progression of kidney disease in a model adjusted for baseline renal function and treatment with RAASB (HR 0.368, p = 0.043), losing its predictive power in a proteinuria-adjusted model. During the follow-up, 45 patients died (20 metformin, 25 non-metformin) and 45 patients suffered a cardiovascular event (15 metformin, 30 non-metformin), with no differences between the two groups. Conclusion Metformin treatment in patients with stage 3 CKD could slow the progression of CKD, this effect should be demonstrated in randomized studies with larger sample size.

scholarly journals Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study

2020 ◽  
Vol 11 (5) ◽  
pp. 1248-1257 ◽  
Author(s):  
Ikuro Matsuba ◽  
Takehiro Kawata ◽  
Kotaro Iemitsu ◽  
Taro Asakura ◽  
Hikaru Amemiya ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Intervention Study ◽  
Progression Of Kidney Disease

Onset and progression of kidney disease in type 2 diabetes among multi-ethnic Asian population

2016 ◽  
Vol 30 (7) ◽  
pp. 1248-1254 ◽  
Author(s):  
Serena Low ◽  
E. Shyong Tai ◽  
Lee Ying Yeoh ◽  
Yan Lun Liu ◽  
Jian Jun Liu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Asian Population ◽  
Progression Of Kidney Disease

400-P: Skin Autofluorescence Is Associated with Progression of Kidney Disease in Individuals with Type 2 Diabetes: Results from the Hong Kong Diabetes Biobank

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 400-P
Author(s):  
QIAO JIN ◽  
ERIC S. LAU ◽  
ANDREA LUK ◽  
RISA OZAKI ◽  
ELAINE CHOW ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Hong Kong ◽  
Kidney Disease ◽  
Skin Autofluorescence ◽  
Progression Of Kidney Disease

Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients

2012 ◽  
Vol 72 (4) ◽  
pp. 333-339 ◽  
Author(s):  
Ina Maria Kacso ◽  
Cosmina Ioana Bondor ◽  
Gabriel Kacso
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Disease ◽  
Plasma Adiponectin ◽  
Progression Of Kidney Disease ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document